Beta-blockers for hypertension: Are they going out of style?

被引：17

作者：

Che, Qi ^{[1
]}

Schreiber, Martin J., Jr. ^{[1
]}

Rafey, Mohammed A. ^{[1
]}

机构：

[1] Cleveland Clin, Glickman Urol & Kidney Inst, Dept Hypertens & Nephrol, Cleveland, OH 44195 USA

来源：

CLEVELAND CLINIC JOURNAL OF MEDICINE | 2009年 / 76卷 / 09期

关键词：

RANDOMIZED-TRIAL; BLOOD-PRESSURE; CARDIOVASCULAR MORBIDITY; ELDERLY-PATIENTS; HEART-FAILURE; MYOCARDIAL-INFARCTION; SWEDISH TRIAL; OLD PATIENTS; MORTALITY; NEBIVOLOL;

D O I：

10.3949/ccjm.76a.09030

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Although beta-blockers lower blood pressure in most patients, the outcomes of clinical hypertension trials of these drugs have been disappointing, and the value of beta-blockers in treating hypertensive patients who do not have compelling indications for them has been questioned. Until these drugs are proved beneficial, they should be used as antihypertensive therapy only in patients with compelling cardiac indications for them or as add-on agents in those with uncontrolled or resistant hypertension.

引用

页码：533 / 542

页数：10

共 66 条

[11] Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) Trial [J].

Black, HR ;

Elliott, WJ ;

Grandits, G ;

Grambsch, P ;

Lucente, T ;

White, WB ;

Neaton, JD ;

Grimm, RH ;

Hansson, L ;

Lacourcière, Y ;

Muller, J ;

Sleight, P ;

Weber, MA ;

Williams, G ;

Wittes, J ;

Zanchetti, A ;

Anders, RJ .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 289 (16) :2073-2082

[12] Cardiovascular risk assessment through target organ damage: Role of carotid to femoral pulse wave velocity [J].

Boutouyrie, Pierre ;

Vermersch, Sebastian ;

Laurent, Stephane ;

Briet, Marie .

CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2008, 35 (04) :530-533

[13] β-adrenergic receptor blockade in chronic heart failure [J].

Bristow, MR .

CIRCULATION, 2000, 101 (05) :558-569

[14] β-blockers in congestive heart failure -: A Bayesian meta-analysis [J].

Brophy, JM ;

Joseph, L ;

Rouleau, JL .

ANNALS OF INTERNAL MEDICINE, 2001, 134 (07) :550-560

[15] Atenolol in hypertension: is it a wise choice? [J].

Carlberg, B ;

Samuelsson, O ;

Lindholm, LJ .

LANCET, 2004, 364 (9446) :1684-1689

[16] Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure [J].

Chobanian, AV ;

Bakris, GL ;

Black, HR ;

Cushman, WC ;

Green, LA ;

Izzo, JL ;

Jones, DW ;

Materson, BJ ;

Oparil, S ;

Wright, JT ;

Roccella, EJ .

HYPERTENSION, 2003, 42 (06) :1206-1252

[17]

COCKCROFT JR, 1995, J PHARMACOL EXP THER, V274, P1067

[18] RANDOMIZED TRIAL OF TREATMENT OF HYPERTENSION IN ELDERLY PATIENTS IN PRIMARY CARE [J].

COOPE, J ;

WARRENDER, TS .

BRITISH MEDICAL JOURNAL, 1986, 293 (6555) :1145-1151

[19] MORBIDITY AND MORTALITY IN THE SWEDISH TRIAL IN OLD PATIENTS WITH HYPERTENSION (STOP-HYPERTENSION) [J].

DAHLOF, B ;

LINDHOLM, LH ;

HANSSON, L ;

SCHERSTEN, B ;

EKBOM, T ;

WESTER, PO .

LANCET, 1991, 338 (8778) :1281-1285

[20] Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE):: a randomised trial against atenolol [J].

Dahlöf, B ;

Devereux, RB ;

Kjeldsen, SE ;

Julius, S ;

Beevers, G ;

de Faire, U ;

Fyhrquist, F ;

Ibsen, H ;

Kristiansson, K ;

Lederballe-Pedersen, O ;

Lindholm, LH ;

Nieminen, MS ;

Omvik, P ;

Oparil, S ;

Wedel, H .

LANCET, 2002, 359 (9311) :995-1003

← 1 2 3 4 5 6 7 →